Biochip allows detection of amphetamine, methamphetamine, cocaine, barbiturates, cannabinoids, opiates, methadone, benzodiazepines, lorazepam, phencyclidine and creatinine from a single urine sample
Randox has received FDA clearance for its Drugs of Abuse array for use on the evidence analyser.
The multi-analyte biochip allows the simultaneous detection of amphetamine, methamphetamine, cocaine, barbiturates, cannabinoids, opiates, methadone, benzodiazepines, lorazepam, phencyclidine and creatinine from a single urine sample.
The company says the evidence analyser is at the forefront of biochip array technology, offering the latest technological advances in clinical analysis.
